

# HEALTHCARE MONTHLY

JULY 2020

*Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.*









BioTech / Pharma

Healthcare Services

Life Sciences / Diagnostics


Medical Devices

## HEADLINE TRANSACTIONS


	TARGET	ACQUIROR	ACQUISITION SYNOPSIS
Medical Devices	 <b>ULTIMED</b> <small>INCORPORATED</small>	 <small>LEVINE LEICHTMAN CAPITAL PARTNERS</small>	<ul style="list-style-type: none"> <li>TM Capital served as exclusive financial advisor to UltiMed, Inc., a portfolio company of LDI, Ltd., in its sale to an investment vehicle sub-managed by Levine Leichtman Capital Partners ("LLCP")</li> <li>UltiMed supplies insulin pen needles, syringes and complementary products for diabetes patients who need daily insulin injections and for companion animals who increasingly suffer from this life-threatening disease</li> <li>LLCP is an independent investment firm that has managed approximately \$11 billion of institutional capital since inception</li> </ul>
Life Sci / Diagnostics	 <b>ARCHER</b> <sup>®</sup>	 <b>INVITAE</b>	<ul style="list-style-type: none"> <li>Invitae Corporation (NYSE:NVTA) entered into a definitive agreement to acquire ArcherDX, Inc. for approximately \$1.4 billion</li> <li>ArcherDX operates as a genomics company in the United States and internationally</li> <li>Invitae Corporation analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients internationally</li> <li>Implied Enterprise Value / LTM Total Revenue Multiple: 24.9x</li> </ul>
BioTech / Pharma	 <b>CORVIDIA</b> <small>Precision Cardiovascular Therapeutics</small>	 <b>novo nordisk</b> <sup>®</sup>	<ul style="list-style-type: none"> <li>Novo Nordisk A/S (CPSE:NOVO B) entered into an agreement to acquire Corvidia Therapeutics, Inc. for approximately \$725 million and up to \$1.4 billion in milestones</li> <li>Corvidia Therapeutics, a clinical stage company, focuses on the development and commercialization of transformative cardiovascular therapies</li> <li>Novo Nordisk is a Danish multinational pharmaceutical company</li> </ul>
	 <b>ENGAGE</b> <small>THERAPEUTICS</small>	 <b>ucb</b>	<ul style="list-style-type: none"> <li>UCB SA (ENXTBR:UCB) acquired Engage Therapeutics, Inc. for approximately \$270 million</li> <li>Engage Therapeutics is a biopharmaceutical company that develops rescue therapy for people who experience uncontrolled epileptic seizures</li> <li>UCB, based in Belgium, develops therapies and solutions for people with immunology diseases in the U.S., Europe and internationally</li> </ul>

# HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins\*



\*EBITDA Margins shown as the gray line.

LTM Stock Price Index



92% BioTech / Pharma    101% Health Services    167% Life Sci / Diagnostics    88% Medical Devices    108% S&P 500 Index

# SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transactions
Takeda Pharmaceuticals' Portfolio Of Select Non-Core OTC & Prescription Pharmaceutical Products	Celltrion, Inc.	The portfolio of non-core OTC & prescription pharmaceutical products comprises the South Korean pharmaceutical products manufacturing business Transaction Value: \$266 million and up to \$12 million in milestones
Engage Therapeutics, Inc.	UCB SA	Engage Therapeutics is a biopharmaceutical company that develops rescue therapy for people who experience uncontrolled epileptic seizures Transaction Value: \$125 million and up to \$145 million in milestones
Rosemont Pharmaceuticals Limited	Inflexion Private Equity Partners LLP	Rosemont Pharmaceuticals Limited manufactures and supplies liquid medicines for patients who have difficulty in swallowing solid medications Transaction Value: \$200 million

Target	Acquiror	Life Sci / Diagnostics Transactions
FTF Pharma Private Limited	Shilpa Medicare Limited	FTF Pharma, based in India, is a contract research organization and engages in the development of generic drugs Transaction Value: \$9.8 million
Clarion Medical Technologies Inc.	Richards Packaging Income Fund	Clarion distributes diagnostic solutions for hospitals, aesthetic clinics and private medical practices Transaction Value: \$64 million
TRSS Co., Ltd.	EP Mediate Co., Ltd.	TRSS provides consulting and outsourcing services for development and diagnostics

Target	Acquiror	Health Services Transactions
PDX, Inc.	Change Healthcare Inc.	PDX offers standardized health information, third party plan information and manufactures & sells point of sale (POS) systems Transaction Value: \$208 million
Ascot Radiology Limited	Integral Diagnostics Limited	Ascot Radiology provides radiology & diagnostic services Transaction Value: \$50 million
Meridian Billing Management Co. and Origin Holdings Inc.	MTBC, Inc.	Meridian and Origin offer electronic billing and electronic medical records outsourcing solutions to the healthcare industry Transaction Value: \$16 million

Target	Acquiror	Medical Device Transactions
Substantially All Assets of Artegraft, Inc.	LeMaitre Vascular, Inc.	Assets include Artegraft's bovine carotid artery grafts manufacturing business Transaction Value: \$72.5 million and up to \$175 million in milestones
S.L.E. Limited	Inspiration Healthcare Group plc	S.L.E. Limited provides neonatal ventilation products Transaction Value: \$22 million
Innovative Technologies LLC	Kapitalinvestproekt JSC	Innovative Technologies manufactures face masks

## Selected TM Capital Healthcare Experience



ULTIMED  
INCORPORATED

A PORTFOLIO COMPANY OF



LDI, Ltd.  
LAW OFFICES

HAS BEEN ACQUIRED BY AN INVESTMENT VEHICLE SUB-MANAGED BY



LL  
LAW OFFICES



METRIGRAPHICS

HAS BEEN ACQUIRED BY




Cirtec  
MEDICAL

A PORTFOLIO COMPANY OF




3i



vip-petcare

HAS BEEN ACQUIRED BY



PETIQ

## TM Capital's Healthcare Industry Contacts



**James McLaren,**  
Managing Director  
jmclaren@tmcapital.com  
212.809.1414



**Michael Goldman,**  
Managing Director  
mgoldman@tmcapital.com  
212.809.1419



**Paul Smolevitz,**  
Managing Director  
psmolevitz@tmcapital.com  
212.809.1416



**John Dean,**  
Vice President  
jdean@tmcapital.com  
404.995.6234



**Steve Hunter,**  
Managing Director - Sponsor Coverage  
mgoldman@tmcapital.com  
404.995.6232